EGFR and non-small cell lung carcinoma: Anlotinib plus platinum and pemetrexed showed promising antitumor activity with manageable toxicity in patients with T790M‐negative EGFR‐mutant advanced nonsquamous NSCLC after progression on first‐ or second‐generation EGFR TKIs.